Evidence map›Paper›PMID 34113571›Full record

ArticleFrontiers in oncology2021

Laterally Extended Endopelvic Resection Versus Chemo or Targeted Therapy Alone for Pelvic Sidewall Recurrence of Cervical Cancer.

Soo Jin Park, Jaehee Mun, Seungmee Lee, Yanlin Luo, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong Sang Song, Hee Seung Kim

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02986568 (Cohort Study for Comparing the Efficacy Between the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02986568 naunknown statusnot on this map

Cohort Study for Comparing the Efficacy Between the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers (FUSION Trial IV)

TypeinterventionalSponsorSeoul National University HospitalRan2016 to 2025Enrolled380ConditionsCervical Cancer, Uterine CancerArmsCervical cancer, Uterine cancer, Cervical cancer, pelvic sidewall invasion, Non-cervical cancer, pelvic sidewall invasion
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Soo Jin ParkDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Jaehee MunDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Seungmee LeeDepartment of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, South Korea.
Yanlin LuoDepartment of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China.
Hyun Hoon ChungDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Jae-Weon KimDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Noh Hyun ParkDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Yong Sang SongDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Hee Seung KimDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Seoul National University · KRHenan Cancer Hospital · CNKeimyung University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLaterally extended endopelvic resection (LEER) has been introduced for treatment of pelvic sidewall recurrence of cervical cancer (PSRCC), which occurs in only 8% of patients with relapsed cervical cancer. LEER can only be performed by a proficient surgeon due to the high risk of surgical morbidity and mortality, but there is no evidence as to whether LEER is may be more effective than chemo or targeted therapy alone for PSRCC. Thus, we aimed to compare the efficacy and safety between LEER and chemo or targeted therapy alone for treatment of PSRCC.

methodsWe prospectively recruited patients with PSRCC who underwent LEER between December 2016 and December 2019. Moreover, we retrospectively collected data on patients with PSRCC who received chemo or targeted therapy alone between January 2000 and December 2019. We compared treatment-free interval (TFI), progression-free survival (PFS), treatment-free survival (TFS), overall survival (OS), tumor response, neurologic disturbance of the low extremities, and pelvic pain severity in the different patient groups.

resultsAmong 1295 patients with cervical cancer, we included 28 (2.2%) and 31 (2.4%) in the prospective and retrospective cohorts, respectively. When we subdivided all patients into two groups based on the median value of prior TFI (PTFI, 9.2 months), LEER improved TFI, PFS, TRS and OS compared to chemo or targeted therapy alone (median, 2.8

conclusionCompared to chemo or targeted therapy alone, LEER improved survival in patients with PSRCC and PTFI < 9.2 months, and it was effective at controlling the pelvic pain associated with PSRCC.

trial registrationClinicalTrials.gov, identifier NCT02986568.

Indexed as

cervical cancerlaterally extended endopelvic resectionpainpelvic sidewall recurrencesurvival

Identifiers

PMID34113571
PMCPMC8186785
OpenAlexW3165686378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.